Skip to main
COYA

COYA Stock Forecast & Price Target

COYA Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Coya Therapeutics is a clinical-stage biotechnology company that is poised for success due to promising results from their ALSTARS phase II trial, positive biomarker data, and a strong intellectual property position. Their combination therapy, COYA-302, has shown potential to enhance the function of regulatory T cells, addressing the underlying immune dysregulation and chronic inflammation believed to drive ALS and other neurodegenerative diseases. While there are risks associated with the company's early stage development programs and the potential for patent infringement, Coya's potential market exclusivity from orphan drug designations and their strong management team make them a promising investment opportunity.

Bears say

Coya Therapeutics is facing multiple risks, including potential failures in its intellectual property protection and challenges in obtaining market exclusivity for its products. In addition, this clinical-stage biotechnology company faces significant competition from larger, more established companies with greater resources and experience. Furthermore, while early clinical data suggests target engagement and safety, the company's therapies may face challenges in achieving clinical endpoints and receiving regulatory approval. Overall, the stock's negative outlook is driven by these fundamental risks and uncertainties that could impact the company's future success in the highly competitive and rapidly evolving biotech industry.

COYA has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Coya Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Coya Therapeutics Inc (COYA) Forecast

Analysts have given COYA a Strong Buy based on their latest research and market trends.

According to 6 analysts, COYA has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Coya Therapeutics Inc (COYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.